Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Jun 24;44(8):941-5.
doi: 10.1038/ng.2329.

De novo somatic mutations in components of the PI3K-AKT3-mTOR pathway cause hemimegalencephaly

Jeong Ho Lee  1 , My Huynh, Jennifer L Silhavy, Sangwoo Kim, Tracy Dixon-Salazar, Andrew Heiberg, Eric Scott, Vineet Bafna, Kiley J Hill, Adrienne Collazo, Vincent Funari, Carsten Russ, Stacey B Gabriel, Gary W Mathern, Joseph G Gleeson
Affiliations

De novo somatic mutations in components of the PI3K-AKT3-mTOR pathway cause hemimegalencephaly

Jeong Ho Lee et al. Nat Genet. .

Abstract

De novo somatic mutations in focal areas are well documented in diseases such as neoplasia but are rarely reported in malformation of the developing brain. Hemimegalencephaly (HME) is characterized by overgrowth of either one of the two cerebral hemispheres. The molecular etiology of HME remains a mystery. The intractable epilepsy that is associated with HME can be relieved by the surgical treatment hemispherectomy, allowing sampling of diseased tissue. Exome sequencing and mass spectrometry analysis in paired brain-blood samples from individuals with HME (n = 20 cases) identified de novo somatic mutations in 30% of affected individuals in the PIK3CA, AKT3 and MTOR genes. A recurrent PIK3CA c.1633G>A mutation was found in four separate cases. Identified mutations were present in 8-40% of sequenced alleles in various brain regions and were associated with increased neuronal S6 protein phosphorylation in the brains of affected individuals, indicating aberrant activation of mammalian target of rapamycin (mTOR) signaling. Thus HME is probably a genetically mosaic disease caused by gain of function in phosphatidylinositol 3-kinase (PI3K)-AKT3-mTOR signaling.

PubMed Disclaimer

Figures

Figure 1
Figure 1
MRI and mutation analysis in hemimegalencephaly. (a) Axial T2-weighted brain MRI of cases identified with mutations. Arrows indicate the affected hemispheres, showing thickened cortical mantle, changes in white matter signal and alterations in ventricular shape, resulting in increased hemispheric size and midline shift of falx cerebri. (b) Sequencing counts from exome sequencing of each of three brain-blood paired samples. Mut, mutation; ref, reference. (c) Mass spectrometry validation of mutations. Wild-type sequences (blue) and de novo mutations (red) are correlated with results from next-generation sequencing.
Figure 2
Figure 2
Consistent de novo mutation burden across affected hemispheres. (a) HME-1573 sampled during surgery in left orbital (Orb), frontal (Fr), central operculum (Co) and occipital (Occ) regions. (b) HME-1656 sampled in parietal (Par), central operculum and temporal (Tem) regions. (c) HME-1563 was sampled multiple independent times in the central operculum region (yellow circles), but samples could not be precisely aligned anatomically. Left, MRI scans; circles indicate brain areas examined by mass spectrometry analysis. Right, each sample aliquot was analyzed by mass spectrometry for mutation burden, describing variation in mutation burden across anatomical locations.
Figure 3
Figure 3
The de novo mutations identified in HME correlate with hyperactive mTOR signaling. (a) Schematic of the PI3K-AKT3-mTOR pathway and downstream phosphorylated ribosomal protein S6 kinase (P-S6K) and phosphorylated ribosomal protein S6 (P-S6). (b) HME pathological samples show an increased percentage of cells with positive staining for P-S6 and MAP2. Left P-S6, biotin-streptavidin DAB staining; right, P-S6, fluorescence-conjugated staining. MAP2 was used to identify neurons. Scale bars, 100 µm. (c) Quantification of P-S6–positive cells from 5–7 representative cortical areas per case. **P < 0.01 (relative to non-HME samples, one-way ANOVA with Bonferroni posttest, n > 50 cells per region). Error bars, s.e.m.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Blümcke I, et al. The clinicopathologic spectrum of focal cortical dysplasias: a consensus classification proposed by an ad hoc Task Force of the ILAE Diagnostic Methods Commission. Epilepsia. 2011;52:158–174. - PMC - PubMed
    1. Barkovich AJ, Guerrini R, Kuzniecky RI, Jackson GD, Dobyns WB. A developmental and genetic classification for malformations of cortical development: update 2012. Brain. 2012;135:1348–1369. - PMC - PubMed
    1. Salamon N, et al. Contralateral hemimicrencephaly and clinical-pathological correlations in children with hemimegalencephaly. Brain. 2006;129:352–365. - PubMed
    1. Di Rocco C, Battaglia D, Pietrini D, Piastra M, Massimi L. Hemimegalencephaly: clinical implications and surgical treatment. Childs Nerv. Syst. 2006;22:852–866. - PubMed
    1. Crino PB. mTOR: a pathogenic signaling pathway in developmental brain malformations. Trends Mol. Med. 2011;17:734–742. - PubMed

Publication types

Substances